SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Schuermans A)
 

Sökning: WFRF:(Schuermans A) > (2023) > Clonal Hematopoiesi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005147naa a2200553 4500
001oai:lup.lub.lu.se:a1559a34-b8c3-4727-9466-37c08bc4c20e
003SwePub
008230810s2023 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/a1559a34-b8c3-4727-9466-37c08bc4c20e2 URI
0247 a https://doi.org/10.1016/j.jacc.2023.03.4012 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Gumuser, Esra D.u Massachusetts General Hospital4 aut
2451 0a Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease
264 1c 2023
300 a 14 s.
520 a Background: Clonal hematopoiesis of indeterminate potential (CHIP)—the age-related clonal expansion of blood stem cells with leukemia-associated mutations—is a novel cardiovascular risk factor. Whether CHIP remains prognostic in individuals with established atherosclerotic cardiovascular disease (ASCVD) is less clear. Objectives: This study tested whether CHIP predicts adverse outcomes in individuals with established ASCVD. Methods: Individuals aged 40 to 70 years from the UK Biobank with established ASCVD and available whole-exome sequences were analyzed. The primary outcome was a composite of ASCVD events and all-cause mortality. Associations of any CHIP (variant allele fraction ≥2%), large CHIP clones (variant allele fraction ≥10%), and the most commonly mutated driver genes (DNMT3A, TET2, ASXL1, JAK2, PPM1D/TP53 [DNA damage repair genes], and SF3B1/SRSF2/U2AF1 [spliceosome genes]) with incident outcomes were compared using unadjusted and multivariable-adjusted Cox regression. Results: Of 13,129 individuals (median age: 63 years) included, 665 (5.1%) had CHIP. Over a median follow-up of 10.8 years, any CHIP and large CHIP at baseline were associated with adjusted HRs of 1.23 (95% CI: 1.10-1.38; P < 0.001) and 1.34 (95% CI: 1.17-1.53; P < 0.001), respectively, for the primary outcome. TET2 and spliceosome CHIP, especially large clones, were most strongly associated with adverse outcomes (large TET2 CHIP: HR: 1.89; 95% CI: 1.40-2.55; P <0.001; large spliceosome CHIP: HR: 3.02; 95% CI: 1.95-4.70; P < 0.001). Conclusions: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a aging
653 a coronary artery disease
653 a inflammation
653 a prevention
653 a risk factor
7001 a Schuermans, Artu Massachusetts Institute of Technology,Massachusetts General Hospital,Catholic University of Leuven4 aut
7001 a Cho, So Mi Jemmau Massachusetts General Hospital,Massachusetts Institute of Technology4 aut
7001 a Sporn, Zachary A.u Massachusetts General Hospital4 aut
7001 a Uddin, Md Mesbahu Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Paruchuri, Kaavyau Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Nakao, Tetsushiu Dana-Farber Cancer Institute,Brigham and Women's Hospital / Harvard Medical School,Massachusetts General Hospital,Massachusetts Institute of Technology4 aut
7001 a Yu, Zhiu Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Haidermota, Sarau Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Hornsby, Whitneyu Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Weeks, Lachelle D.u Dana-Farber Cancer Institute4 aut
7001 a Niroula, Abhisheku Lund University,Lunds universitet,Hematogenomics,Forskargrupper vid Lunds universitet,Lund University Research Groups,Dana-Farber Cancer Institute,Massachusetts Institute of Technology4 aut0 (Swepub:lu)med-anu
7001 a Jaiswal, Siddharthau Stanford University School of Medicine4 aut
7001 a Libby, Peteru Brigham and Women's Hospital / Harvard Medical School4 aut
7001 a Ebert, Benjamin L.u Dana-Farber Cancer Institute4 aut
7001 a Bick, Alexander G.u Vanderbilt University Medical Center4 aut
7001 a Natarajan, Pradeepu Massachusetts Institute of Technology,Massachusetts General Hospital4 aut
7001 a Honigberg, Michael C.u Massachusetts General Hospital,Massachusetts Institute of Technology4 aut
7102 a Massachusetts General Hospitalb Massachusetts Institute of Technology4 org
7730 t Journal of the American College of Cardiologyg 81:20, s. 1996-2009q 81:20<1996-2009x 0735-1097
8564 u http://dx.doi.org/10.1016/j.jacc.2023.03.401y FULLTEXT
8564 8u https://lup.lub.lu.se/record/a1559a34-b8c3-4727-9466-37c08bc4c20e
8564 8u https://doi.org/10.1016/j.jacc.2023.03.401

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy